Shanghai Fosun Pharmaceutical Group Co Ltd 2022 SR
The report highlights Fosun Pharma's 2022 performance, focusing on innovation for health. Key achievements include the launch of Azvudine, China's first oral anti-COVID-19 drug, and treating over 56 million malaria patients with Artesun. The company invested RMB 5.885 billion in R&D and achieved an MSCI ESG rating of A. Environmental efforts led to a 6.18% reduction in carbon emission intensity and the purchase of 16.92 million kWh of green electricity. Social initiatives included the 'Fosun Care 121' fund and rural revitalization projects.
Company: Shanghai Fosun Pharmaceutical Group Co Ltd
Sector: Health Care
Country: China
Year: 2022
Type: SR
Pages: 140
Shanghai Fosun Pharmaceutical Group Co Ltd
Corporate Social Responsibility Report
The report highlights Fosun Pharma's 2022 performance, focusing on innovation for health. Key achievements include the launch of Azvudine, China's first oral anti-COVID-19 drug, and treating over 56 million malaria patients with Artesun. The company invested RMB 5.885 billion in R&D and achieved an MSCI ESG rating of A. Environmental efforts led to a 6.18% reduction in carbon emission intensity and the purchase of 16.92 million kWh of green electricity. Social initiatives included the 'Fosun Care 121' fund and rural revitalization projects.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Workplace Fatalities
Employees